MedTrace Logo

The MARVIN Chatbots to Provide Information for Different Health Conditions

NCT05789901 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-03-06

No results posted yet for this study

Summary

This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.

Conditions

Interventions

OTHER

MARVIN

Chatbot on Meta (Facebook) Messenger for HIV Patients

OTHER

MARVIN-Pharma

Chatbot on Meta (Facebook) Messenger for community pharmacists

OTHER

MARVINA

Chatbot on Meta (Facebook) Messenger for breast cancer patients

OTHER

MARVIN-CHAMP

CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)

Sponsors & Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Bertrand Lebouché, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2033-12-31
Completion
2034-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05789901 on ClinicalTrials.gov